Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. - Wikidata - wikimedia - TriplyDB

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

http://www.wikidata.org/entity/Q34333511

about

Ocular indicators of Alzheimer's: exploring disease in the retina Amyloid-β plaque deposition measured using propagation-based X-ray phase contrast CT imaging.Recent imaging advances in neurology.Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.Self-reported confusion is related to global and regional β-amyloid: data from the Women's healthy ageing project.Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say.Correlation between two methods of florbetapir PET quantitative analysis.The evolution of preclinical Alzheimer's disease: implications for prevention trials.PET Imaging of Tau Pathology in Alzheimer's Disease and Tauopathies.Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort.Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.An Alzheimer's Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults.Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study.Homogeneous clusters of Alzheimer's disease patient population Clusters of male and female Alzheimer's disease patients in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.Aberrant brain stem morphometry associated with sleep disturbance in drug-naïve subjects with Alzheimer's disease Nonvascular retinal imaging markers of preclinical Alzheimer's disease.Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.Multicenter stability of resting state fMRI in the detection of Alzheimer's disease and amnestic MCI.Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.Early and Late Pathomechanisms in Alzheimer's Disease: From Zinc to Amyloid-β Neurotoxicity PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease.Advanced imaging of tau pathology in Alzheimer Disease: New perspectives from super resolution microscopy and label-free nanoscopy.Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later.Amyloid Imaging: Poised for Integration into Medical Practice.Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis.Brain Amyloid Deposition Is Associated With Lower Instrumental Activities of Daily Living Abilities in Older Adults. Results From the MAPT Study.AβPP-Transgenic 2576 Mice Mimic Cell Type-Specific Aspects of Acetyl-CoA-Linked Metabolic Deficits in Alzheimer's Disease.Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.

P2860

Q28078670-F2831A51-6D37-4B65-8C0E-A2F04211897A Q30839078-CE3E6AB9-9CCF-4BFE-B38C-9DC3E723F66D Q30916063-344C533D-BC24-41DB-A792-70C8CB4B9994 Q30930965-C692F8C0-2858-4B05-820F-82DE9E90AFB5 Q31096423-7CACA081-6290-436C-B74A-EB6B7B80740C Q31155701-96757AF3-C9AA-4575-8C2C-498638CE8B33 Q33604453-214D061A-D6D4-4F1D-83B1-CC10C22D908F Q33642389-AD078DFD-B7F8-40B0-8FF4-45CB7BAEE30C Q33905494-EB8C97A9-35F0-4109-8C2F-2D414A819080 Q34849048-AD2EF910-1E3F-4C93-8980-FCFE7547685B Q35158227-9A61C55E-0DC5-4E38-A8CF-28CE201CCB2A Q35576440-A609BF08-EF0F-437C-BFBA-F5CAE0D65D27 Q35803904-DAABE01A-52C4-42B9-86F9-479AE5C72CBA Q35905536-DF88A662-C20A-4CB8-BB59-B441C4CBB61F Q36351585-85289E4D-2DD9-4F1B-B2A4-FB17A2DCDD6E Q36456068-C68C482F-9A6E-41ED-BE83-473C561D7ACF Q36850584-3758F268-47FB-4C33-AD87-C2938171FF6D Q36929890-1EE90ADD-D6D8-4481-9CDF-ED23BE4D5CA0 Q36934154-E1F1A625-0B67-4A6F-9214-8FFD9B0BF372 Q37053816-8C9D4E6C-2BBD-46E7-98F9-DCDACCCF29B5 Q37096748-27B13A48-EDAE-4513-9F34-7ABC6CDE0656 Q37100074-56F1E53E-EA0B-4140-A0A1-E4F5214DF722 Q37122660-1A030E0C-D388-4FD9-B2DA-27D295F14802 Q37131886-85A8E887-C9AC-4508-9958-601EAE17B98E Q37213267-9D335979-E0BE-4C31-B972-634808B28135 Q37363628-A17228CA-F9E5-4AE1-B171-2469551D526F Q37520832-9E5721D4-BBE3-446F-A3FA-BC53110945CC Q37613576-9C78E125-32AB-4838-8844-DD6655CC724C Q37650253-0A32378F-DADD-4DC5-9BF7-57B088F19625 Q37710159-A3995D17-0011-4545-9030-B77469F4FD7A Q37718557-D0E105CB-BB87-42AB-8EDA-623CC6CE2570 Q38654257-3EFBE5E6-9C98-4C6D-9BE3-5D28A1F5D137 Q38870940-376EBD8B-EF9E-4D79-A2E0-94DB8A06D477 Q38873806-49C1AEB5-9990-4238-8387-28DB22DF22FD Q38939875-453929B5-88C9-4EF3-978F-43FB2B35B53B Q39219904-D708773A-DD37-4B06-B435-507610739CF6 Q39301541-046B5535-48F3-4888-982F-04CE62B8C878 Q40485355-E73CB9A9-8D6A-482E-AF91-EC5D2FABA16E Q40506883-0637B7FC-D60B-4101-BD53-BD4B4B91AD2E Q41084541-D91D3F39-DC7E-4849-80A3-05B35899F7E9

P2860

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

http://www.wikidata.org/entity/Q34333511

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@ast

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@en

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@nl

type

label

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@ast

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@en

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@nl

prefLabel

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@ast

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@en

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@nl

P1433

Q34333511-458F6011-2CAD-4A89-A16A-F5F546E1C622

P1476

Q34333511-AFE5B3DC-A785-4768-B84E-9E959069C4FA

P2093

Q34333511-24179345-F5C5-41BB-A661-FD472E1203DA

Q34333511-398114F2-7B83-4816-A37C-D2F7B5E60277

Q34333511-45523E9E-021F-4B7A-A9FA-4E94FDF20249

Q34333511-6B3E34FC-23B8-4F4B-9029-909CB05051FC

Q34333511-70A810AA-FAA1-44A3-A820-BDC756776BFF

Q34333511-7552F80B-C9E4-4415-8FF3-7252D0447C52

Q34333511-77A5936E-4115-49FB-A799-D23F87B22858

Q34333511-7D91E836-F7C0-48CF-9B36-BA6297FAD874

Q34333511-8EFDDDFA-72AB-438F-9DFF-AD4F6E1B7AF8

Q34333511-9B913E0D-B982-454A-A5C5-E89451A87798

P2860

Q34333511-05C3352D-97A9-4B04-BBBD-7316864CECAA

Q34333511-08021D6D-B73D-46C1-B999-F1B48B80C6FD

Q34333511-2C250271-CB27-40AD-97C6-CF117FDB7BDD

Q34333511-361DA5D3-0D6B-47A7-98E0-242303365744

Q34333511-3C5A32A5-B8FF-4FDA-B213-A60A83953A82

Q34333511-3FBFB559-AB90-46F9-B708-9F4EF65E7637

Q34333511-4454A4DF-4A8B-4C87-B8B9-219FA297A4FF

Q34333511-46CA7650-F4E7-4792-9408-E1009665D69B

Q34333511-4C9A4776-0A46-4109-A6F9-8524086BB4A7

Q34333511-5472DFFD-A35A-4E9E-8401-2B45341903F0

P2888

Q34333511-E6837B51-C1BD-4561-9EA8-1AE73C62B1F7

P304

Q34333511-3C5BD34E-81B9-441E-8FC8-016FBA37FE39

P31

Q34333511-BFAD12A4-2F6A-441B-8986-F3BE8F2B4CAC

P356

Q34333511-0E6061D6-A738-4D65-8B8C-598CCF6090AE

P407

Q34333511-83D510E4-D26C-469F-AE1A-347D7BCA85DF

P433

Q34333511-042FE135-E539-42C7-9B57-22AED17C769C

P478

Q34333511-80FD5531-6BFD-4F9F-BD08-7A1D1AEBDB20

P50

Q34333511-EE7467C4-240F-42B0-BCEF-D2AB3D2D1BCF

P577

Q34333511-A2C339EF-1E7D-4F04-9C52-2FCC0E22D261

P5875

Q34333511-C5ED3CDE-160B-4C86-915A-D892E2A696D8

P698

Q34333511-706DB358-A54D-419C-A08E-881A27C497DC

P921

Q34333511-946C6320-9F77-4C35-8F1D-A61FF8E1EBF3

P932

Q34333511-CCAF2921-89F5-4FE5-8EE9-633EC0D7485A

P356

P1433

Molecular Psychiatry

P1476

Florbetapir F 18 amyloid PET a ...... prospective multicenter study.

@en

P2093

A Carpenter

http://www.w3.org/2001/XMLSchema#string

A D Joshi

http://www.w3.org/2001/XMLSchema#string

A S Fleisher

http://www.w3.org/2001/XMLSchema#string

AV45-A11 Study Group

http://www.w3.org/2001/XMLSchema#string

C H Sadowsky

http://www.w3.org/2001/XMLSchema#string

D M Skovronsky

http://www.w3.org/2001/XMLSchema#string

E M Reiman

http://www.w3.org/2001/XMLSchema#string

K Johnson

http://www.w3.org/2001/XMLSchema#string

M Grundman

http://www.w3.org/2001/XMLSchema#string

M J Pontecorvo

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

The Alzheimer's disease neuroimaging initiative: progress report and future plans

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study.

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

P2888

P304

1044-1051

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MP.2014.9

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262046811

http://www.w3.org/2001/XMLSchema#string

P698

24614494

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4195975

http://www.w3.org/2001/XMLSchema#string